Imunon, Inc.

LSE:0HUZ Stock Report

Market Cap: US$11.8m

Imunon Valuation

Is 0HUZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0HUZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0HUZ's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0HUZ's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0HUZ?

Key metric: As 0HUZ is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 0HUZ. This is calculated by dividing 0HUZ's market cap by their current book value.
What is 0HUZ's PB Ratio?
PB Ratio1.4x
BookUS$8.19m
Market CapUS$11.77m

Price to Book Ratio vs Peers

How does 0HUZ's PB Ratio compare to its peers?

The above table shows the PB ratio for 0HUZ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average2.6x
OPTI OptiBiotix Health
1.7xn/aUK£12.2m
LLAI LungLife AI
0.4x101.0%UK£2.8m
APTA Aptamer Group
7.4xn/aUK£6.5m
VRCI Verici Dx
1xn/aUK£8.2m
0HUZ Imunon
1.4x-22.0%US$11.8m

Price-To-Book vs Peers: 0HUZ is good value based on its Price-To-Book Ratio (1.4x) compared to the peer average (2.6x).

Price to Book Ratio vs Industry

How does 0HUZ's PB Ratio compare vs other companies in the GB Biotechs Industry?

4 CompaniesPrice / BookEstimated GrowthMarket Cap
DEST Destiny Pharma
0.3x-15.5%US$5.85m
BDRX Biodexa Pharmaceuticals
0.5xn/aUS$4.42m
LLAI LungLife AI
0.4x101.0%US$3.45m
VAL ValiRx
0.6xn/aUS$2.77m
No more companies available in this PB range
0HUZ 1.4xIndustry Avg. 2.9xNo. of Companies7PB02.44.87.29.612+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 0HUZ is good value based on its Price-To-Book Ratio (1.4x) compared to the UK Biotechs industry average (2.9x).

Price to Book Ratio vs Fair Ratio

What is 0HUZ's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0HUZ PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.4x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 0HUZ's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0HUZ forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.80
US$13.20
+1,541.4%
63.1%US$29.00US$5.00n/a5
Nov ’25US$0.93
US$13.60
+1,357.7%
61.1%US$29.00US$5.00n/a5
Oct ’25US$1.04
US$13.60
+1,214.0%
61.1%US$29.00US$5.00n/a5
Sep ’25US$1.15
US$9.75
+749.3%
35.8%US$14.00US$5.00n/a4
Aug ’25US$1.35
US$10.00
+642.3%
16.3%US$12.00US$8.00n/a3
Jul ’25US$1.21
US$10.00
+725.5%
16.3%US$12.00US$8.00n/a3
Jun ’25US$1.42
US$10.00
+603.2%
16.3%US$12.00US$8.00n/a3
May ’25US$1.28
US$12.00
+837.5%
24.5%US$15.00US$8.00n/a3
Apr ’25US$1.77
US$12.00
+577.2%
24.5%US$15.00US$8.00n/a3
Mar ’25US$1.14
US$11.67
+922.2%
24.6%US$15.00US$8.00n/a3
Feb ’25US$0.52
US$11.67
+2,165.4%
24.6%US$15.00US$8.00n/a3
Jan ’25US$0.72
US$11.67
+1,520.4%
24.6%US$15.00US$8.00n/a3
Dec ’24US$0.91
US$11.67
+1,182.1%
24.6%US$15.00US$8.00n/a3
Nov ’24US$1.00
US$11.67
+1,067.9%
24.6%US$15.00US$8.00US$0.933
Oct ’24US$0.91
US$12.50
+1,267.6%
23.0%US$15.00US$8.00US$1.044
Sep ’24US$1.22
US$17.25
+1,311.4%
33.4%US$27.00US$12.00US$1.154
Aug ’24US$1.27
US$17.25
+1,258.3%
33.4%US$27.00US$12.00US$1.354
Jul ’24n/a
US$17.25
0%
33.4%US$27.00US$12.00US$1.214
Jun ’24US$1.23
US$17.25
+1,302.4%
33.4%US$27.00US$12.00US$1.424
May ’24US$1.23
US$19.67
+1,494.2%
26.7%US$27.00US$15.00US$1.283
Apr ’24US$1.34
US$19.67
+1,367.7%
26.7%US$27.00US$15.00US$1.773
Mar ’24US$1.44
US$23.25
+1,513.4%
54.1%US$45.00US$15.00US$1.144
Feb ’24US$1.55
US$23.25
+1,400.0%
54.1%US$45.00US$15.00US$0.524
Jan ’24US$1.36
US$23.25
+1,609.6%
54.1%US$45.00US$15.00US$0.724
Dec ’23US$1.46
US$23.25
+1,490.7%
54.1%US$45.00US$15.00US$0.914
Nov ’23US$1.60
US$24.00
+1,400.0%
51.1%US$45.00US$15.00US$1.004

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€62.90

7D

1.5%

1Y

14.6%

hVIVO

UK£149.7m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.22

7D

-16.2%

1Y

22.2%

Regeneron Pharmaceuticals

US$79.4b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$748.39

7D

-1.7%

1Y

-6.3%